Vitamin D Deficiency May Increase Relapse Risk Among Patients With Myeloid Malignancies

Share this content:
Patients with vitamin D deficiency had a higher risk of relapse; deficiency was also associated with a trend towards inferior survival.
Patients with vitamin D deficiency had a higher risk of relapse; deficiency was also associated with a trend towards inferior survival.

Patients with myeloid malignancies who have vitamin D deficiency prior to allogeneic stem cell transplantation (alloSCT) have an increased risk of relapse, according to a study published in the Journal of Clinical Oncology.1

To determine the prognostic relevance of vitamin D deficiency in this setting, researchers analyzed the outcomes of 492 patients in a training cohort and 398 patients in a validation cohort. Eligible patients had a myeloid or lymphoid malignancy, underwent alloSCT, and had validated records of pre-transplant vitamin D levels.

Vitamin D deficiency was noted in 80% of patients in the training cohort and 87% of patients in the validation cohort prior to allograft. Median follow-up was 51.2 months.

Patients in the training cohort with vitamin D deficiency had a higher risk of relapse (hazard ratio [HR], 1.96; P = .006); deficiency was also associated with inferior overall survival (OS; HR, 1.78; P = .006).

Patients with vitamin D deficiency also trended higher towards an increased risk of non-relapse mortality (NRM) (HR, 1.72; P = .088).

Patients with myeloid malignancies who were vitamin D deficient prior to alloSCT exhibited worse outcomes for overall mortality and NRM, but only the risk of relapse was significant (HR, 2.55; P = .014).

RELATED: Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL

Vitamin D deficiency in patients with lymphoid malignancies was not associated with an increased risk of relapse, but was linked with a trend towards higher NRM (HR, 2.55; P = .078) and an inferior OS (HR, 2.06; P = .031).

In the validation cohort, there was not an increased risk for NRM, but there was an increased risk for relapse in pre-transplant vitamin D–deficient patients, though it did not negatively affect OS rates.

Reference

  1. Radujkovic A, Kordelas L, Krzykalla J, et al. Pretransplant vitamin D deficiency is associated with higher relapse rates in patients allografted for myeloid malignancies. J Clin Oncol. 2017 Aug 3. doi: 10.1200/JCO.2017.73.0085 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters